{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:06:23Z","timestamp":1780707983766,"version":"3.54.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>It is unclear whether spironolactone reduced heart failure (HF) hospitalizations in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial through potential diuretic or other effects. We examined the effects of spironolactone on weight, diuretic use, and renal function, and their subsequent impact on outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We analysed data from TOPCAT Americas (1767 patients with HF and preserved ejection fraction; 886 in spironolactone, 881 in placebo arm). We used mixed-effects models for serial data and shared frailty models to identify determinants of recurrent HF hospitalizations among baseline and serial parameters. There were 800 HF hospitalizations after a median of 3.0\u2009years. Despite more weight loss with spironolactone initially, weight trajectories overlapped after 12\u2009months. Daily furosemide dose (time-averaged \u0394: \u22124.8% vs. +11.6%, P &amp;lt;\u20090.001) and thiazide use (\u22124.3% vs. +1.7%; P =\u20090.003) decreased with spironolactone; however, angiotensin-converting enzyme inhibitor (ACEI)\/angiotensin receptor blocker (ARB) use decreased also (\u221213.1% vs. \u22127.3%; P =\u20090.004). Serum creatinine increased more with spironolactone (+12.5% vs. +3.5%; P &amp;lt;\u20090.001). In time-updated models, loop diuretic dose [hazard ratio (HR) per doubling 1.21; 95% confidence interval (CI) 1.10\u20131.32; P &amp;lt;\u20090.001], creatinine (HR per doubling 1.28; 95% CI 1.04\u20131.40; P =\u20090.019), and ACEI\/ARB use (HR 0.82; 95% CI 0.67\u20131.00; P =\u20090.048) were associated with HF hospitalizations. However, the effect of spironolactone on HF hospitalizations persisted (HR 0.77; 95% CI 0.62\u20130.96; P =\u20090.021) in these models. Results were similar for cardiovascular mortality and time to first HF hospitalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In TOPCAT Americas, the benefit of spironolactone on outcomes could not be solely attributed to potential diuretic effects, suggesting the presence of non-diuretic mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.1917","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T05:20:13Z","timestamp":1590729613000},"page":"1600-1610","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Diuretic and Renal Effects of Spironolactone and Heart Failure Hospitalizations: A TOPCAT Americas Analysis"],"prefix":"10.1093","volume":"22","author":[{"given":"Andreas P.","family":"Kalogeropoulos","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Stony Brook University , Stony Brook, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincy","family":"Thankachen","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Stony Brook University , Stony Brook, NY ,","place":["USA"]},{"name":"Division of Cardiology, Jacobi Medical Center , Bronx, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi , Jackson, MS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Fang","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Utah , Salt Lake City, UT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"2026011721371626700_ejhf1917-bib-0001","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026011721371626700_ejhf1917-bib-0002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026011721371626700_ejhf1917-bib-0003","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ejhf.1060","article-title":"Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial","volume":"20","author":"Selvaraj","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026011721371626700_ejhf1917-bib-0004","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1517\/13543784.10.5.943","article-title":"The spironolactone renaissance","volume":"10","author":"Doggrell","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"2026011721371626700_ejhf1917-bib-0005","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT \u2013 new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"key":"2026011721371626700_ejhf1917-bib-0006","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","article-title":"Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction","volume":"11","author":"Selvaraj","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026011721371626700_ejhf1917-bib-0007","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ije\/dyu222","article-title":"Modelling recurrent events: a tutorial for analysis in epidemiology","volume":"44","author":"Amorim","year":"2015","journal-title":"Int J Epidemiol"},{"key":"2026011721371626700_ejhf1917-bib-0008","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1536867X0200200102","article-title":"Parametric frailty and shared frailty survival models","volume":"2","author":"Gutierrez","year":"2002","journal-title":"Stata J"},{"key":"2026011721371626700_ejhf1917-bib-0009","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/(SICI)1097-0258(20000115)19:1<13::AID-SIM279>3.0.CO;2-5","article-title":"Survival analysis for recurrent event data: an application to childhood infectious diseases","volume":"19","author":"Kelly","year":"2000","journal-title":"Stat Med"},{"key":"2026011721371626700_ejhf1917-bib-0010","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/CIRCHEARTFAILURE.113.001281","article-title":"Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction","volume":"7","author":"Bello","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721371626700_ejhf1917-bib-0011","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/sim.5639","article-title":"Comparison between splines and fractional polynomials for multivariable model building with continuous covariates: a simulation study with continuous response","volume":"32","author":"Binder","year":"2013","journal-title":"Stat Med"},{"key":"2026011721371626700_ejhf1917-bib-0012","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1002\/sim.8336","article-title":"Mediation analysis of time-to-event endpoints accounting for repeatedly measured mediators subject to time-varying confounding","volume":"38","author":"Vansteelandt","year":"2019","journal-title":"Stat Med"},{"key":"2026011721371626700_ejhf1917-bib-0013","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/ejhf.1228","article-title":"Exercise elicits dynamic changes in extravascular lung water and haemodynamic congestion in heart failure patients with preserved ejection fraction","volume":"20","author":"Simonovic","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026011721371626700_ejhf1917-bib-0014","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/ejhf.1050","article-title":"Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion","volume":"20","author":"Van Aelst","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026011721371626700_ejhf1917-bib-0015","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMra1703100","article-title":"Diuretic treatment in heart failure","volume":"377","author":"Ellison","year":"2017","journal-title":"N Engl J Med"},{"key":"2026011721371626700_ejhf1917-bib-0016","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.amjcard.2005.12.072","article-title":"Relation of loop diuretic dose to mortality in advanced heart failure","volume":"97","author":"Eshaghian","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026011721371626700_ejhf1917-bib-0017","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ejheart.2007.07.011","article-title":"Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial","volume":"9","author":"Hasselblad","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026011721371626700_ejhf1917-bib-0018","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000164149","article-title":"Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry","volume":"113","author":"Peacock","year":"2009","journal-title":"Cardiology"},{"key":"2026011721371626700_ejhf1917-bib-0019","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/hrt.57.1.17","article-title":"Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics","volume":"57","author":"Bayliss","year":"1987","journal-title":"Br Heart J"},{"key":"2026011721371626700_ejhf1917-bib-0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1388-9842(02)00205-2","article-title":"Neurohormonal effects of furosemide withdrawal in elderly heart failure patients with normal systolic function","volume":"5","author":"van Kraaij","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"2026011721371626700_ejhf1917-bib-0021","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.CIR.100.12.1311","article-title":"Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction","volume":"100","author":"Cooper","year":"1999","journal-title":"Circulation"},{"key":"2026011721371626700_ejhf1917-bib-0022","first-page":"331","article-title":"Relationship between heart failure treatment and development of worsening renal function among hospitalized patients","volume":"147","author":"Butler","year":"2004","journal-title":"Am Heart J"},{"key":"2026011721371626700_ejhf1917-bib-0023","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ahj.2010.05.032","article-title":"Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization","volume":"160","author":"Abdel-Qadir","year":"2010","journal-title":"Am Heart J"},{"key":"2026011721371626700_ejhf1917-bib-0024","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.ahj.2011.03.028","article-title":"Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-Stage Disease Intervention Trial (PREVEND IT)","volume":"161","author":"Brouwers","year":"2011","journal-title":"Am Heart J"},{"key":"2026011721371626700_ejhf1917-bib-0025","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1161\/CIRCULATIONAHA.107.762229","article-title":"Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial","volume":"118","author":"Davis","year":"2008","journal-title":"Circulation"},{"key":"2026011721371626700_ejhf1917-bib-0026","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ejhf.76","article-title":"Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial","volume":"16","author":"Jhund","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011721371626700_ejhf1917-bib-0027","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"2026011721371626700_ejhf1917-bib-0028","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026011721371626700_ejhf1917-bib-0029","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1161\/CIRCULATIONAHA.116.022249","article-title":"Heart failure with preserved ejection fraction: a kidney disorder?","volume":"134","author":"Fang","year":"2016","journal-title":"Circulation"},{"key":"2026011721371626700_ejhf1917-bib-0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejim.2013.11.007","article-title":"Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review","volume":"25","author":"Mavrakanas","year":"2014","journal-title":"Eur J Intern Med"},{"key":"2026011721371626700_ejhf1917-bib-0031","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026011721371626700_ejhf1917-bib-0032","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0735-1097(02)02382-3","article-title":"Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy","volume":"40","author":"Rousseau","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026011721371626700_ejhf1917-bib-0033","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1007\/s00392-015-0877-5","article-title":"Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms","volume":"104","author":"Vizzardi","year":"2015","journal-title":"Clin Res Cardiol"},{"key":"2026011721371626700_ejhf1917-bib-0034","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1161\/CIRCHEARTFAILURE.115.002249","article-title":"Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"8","author":"Shah","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026011721371626700_ejhf1917-bib-0035","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1161\/CIRCULATIONAHA.115.015884","article-title":"Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"132","author":"Shah","year":"2015","journal-title":"Circulation"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.1917","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.1917","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.1917","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/22\/9\/1600\/66111805\/eurjhf_22_9_1600.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/22\/9\/1600\/66111805\/eurjhf_22_9_1600.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:39:38Z","timestamp":1768703978000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/22\/9\/1600\/8384631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,6,26]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.1917","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,6,26]]},"assertion":[{"value":"2019-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}